Effective management strategies for patients with marginal zone lymphoma
نویسندگان
چکیده
منابع مشابه
Surgical management of splenic marginal zone lymphoma.
OBJECTIVES Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma with variable prognosis. As a result, there is sparse knowledge on the role of splenectomy and best management approaches. We aim to explore management strategies and outcomes amongst the cohort of SMZL patients at our centre. METHOD A retrospective review of all splenectomies performed at a tertiary referral ...
متن کاملSplenic marginal zone lymphoma.
Splenic marginal zone lymphoma (SMZL) is a specific low-grade small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and relative indolent course. Tumor progression with increase of blasti...
متن کاملRadiotherapy in marginal zone lymphoma
PURPOSE To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone lymphoma (MZL). MATERIALS AND METHODS Patients with stage I (n = 22) and stage II (n = 8) MZL, who were treated with RT were reviewed. The primary tumor localisation was in the orbita (n = 12), stomach (n = 8), head and neck other than the orbita (n = 8), breast (n = 1) and one case of mar...
متن کاملMarginal Zone B-cell lymphoma
Extra-nodal MZBCL of MALT type (7% of all NHL) is an indolent disease involving most often the stomach, where it usually follows chronic gastritis due to Helicobacter pylori (HP) infection. The disease may also localize in the lung, the thyroid, the salivary gland, the orbit. Splenic MZBCL (1% of all NHL on histologic samples) usually, though not invariably, presents splenomegaly associated cir...
متن کاملOptimizing therapy for nodal marginal zone lymphoma.
Nodal marginal zone lymphoma (NMZL) is a rare form of indolent small B-cell lymphoma which has only been clearly identified in the last 2 decades and which to date remains incurable. Progress in therapeutic management has been slow, largely due to the very small number of patients treated and the heterogeneity of treatments administered; thus, standard-of-care treatment is currently nonspecific...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2018
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon-2017-0480